Product Websites

AMEVIVE is a biologic therapy, a new treatment option for adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Commonly observed adverse events that occurred in clinical studies more frequently with AMEVIVE® (alefacept) included: sore throat, dizziness, increased cough, nausea, itching, muscle aches, chills, injection site pain, injection site inflammation, and accidental injury. AMEVIVE must be administered under the supervision of a physician.

AMEVIVE reduces lymphocyte counts (also called T cells). T cell levels should be measured weekly during the 12-week dosing period. AMEVIVE reduces immune cell counts which could increase your chance of developing infection or malignancy, which you should discuss with your doctor. If you develop any signs of infection or malignancy while undergoing a course of treatment with AMEVIVE, you should notify your doctor.

AMEVIVE should not be taken if you are known to be allergic to AMEVIVE or any of its components. If you become pregnant while you are receiving AMEVIVE or within 8 weeks of finishing AMEVIVE, notify your doctor and consider enrolling in the Pregnancy Registry by calling 1-866-AMEVIVE.

For full PRESCRIBING INFORMATION for AMEVIVEi (alefacept) please visit: www.amevive.com.

About AVONEX® (Interferon beta-1a)

AVONEX is the leading treatment for relapsing forms of multiple sclerosis worldwide, with more than 120,000 patients on therapy. It was launched in the U.S. in 1996 and later in Europe for the treatment of relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX is marketed internationally in more than 65 countries.

The most common side effects associated with AVONEX® treatment are flu-like symptoms, muscle ache, fever, and chills. Other common side effects seen, but not statistically different from placebo, were headache (AVONEX®: 67%, placebo: 57%), pain (AVONEX®: 24%, placebo: 20%), and asthenia (weakness) (AVONEX®: 21%, placebo: 13%).

AVONEX® should be used with caution in people with depression and in people with seizure disorders. AVONEX® should not be used by pregnant women. People with cardiac disease should be closely monitored. Routine periodic blood chemistry and hematology tests are recommended during treatment with AVONEX®.

Please see FULL PRESCRIBING INFORMATION for AVONEX® (Interferon beta-1a) on www.AVONEX.com.